202 related articles for article (PubMed ID: 18174638)
1. Novel phosphodiesterase-5 inhibitors: current indications and future directions.
Sharma R
Indian J Med Sci; 2007 Dec; 61(12):667-79. PubMed ID: 18174638
[TBL] [Abstract][Full Text] [Related]
2. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Chrysant SG
Curr Hypertens Rep; 2013 Oct; 15(5):475-83. PubMed ID: 23917809
[TBL] [Abstract][Full Text] [Related]
4. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.
Tzoumas N; Farrah TE; Dhaun N; Webb DJ
Br J Pharmacol; 2020 Dec; 177(24):5467-5488. PubMed ID: 31721165
[TBL] [Abstract][Full Text] [Related]
5. Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.
Al-Ameri H; Kloner RA
Int J Impot Res; 2009; 21(3):149-57. PubMed ID: 19387454
[TBL] [Abstract][Full Text] [Related]
6. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Liu Y
Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1147-51. PubMed ID: 24432631
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Ioakeimidis N; Kostis JB
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications.
Ala M; Mohammad Jafari R; Dehpour AR
Fundam Clin Pharmacol; 2021 Apr; 35(2):235-259. PubMed ID: 33226665
[TBL] [Abstract][Full Text] [Related]
10. [Sex, erectile dysfunction, and the heart: a growing problem].
Görge G; Flüchter S; Kirstein M; Kunz T
Herz; 2003 Jun; 28(4):284-90. PubMed ID: 12825143
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
[TBL] [Abstract][Full Text] [Related]
12. The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Chrysant SG; Chrysant GS
J Clin Hypertens (Greenwich); 2012 Sep; 14(9):644-9. PubMed ID: 22947364
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
14. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase-5 inhibitors: future perspectives.
Konstantinos G; Petros P
Curr Pharm Des; 2009; 15(30):3540-51. PubMed ID: 19860699
[TBL] [Abstract][Full Text] [Related]
16. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
17. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
Kukreja RC; Salloum FN; Das A; Koka S; Ockaili RA; Xi L
Exp Clin Cardiol; 2011; 16(4):e30-5. PubMed ID: 22131856
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
19. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
20. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S
Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]